Insulin Pumps, Continuous Glucose Monitoring, Products Contributing to the Delivery of Hybrid Closed Loop Pathways and Associated Products

Tender description

This Framework Agreement is for the supply of Insulin Pumps, Continuous Glucose Monitoring, Products Contributing to the Delivery of Hybrid Closed Loop Pathways and Associated Products. This includes but not limited to tethered and patch insulin pumps, continuous glucose monitoring devices, products that contribute to the functionality of hybrid closed loop insulin delivery systems, and consumables. Precise quantities are unknown. It is anticipated in the first year that spend will be approximately £210,000,000 - £250,000,000 GBP, however this is approximate only and may vary depending on requirements of bodies purchasing under the Framework. The Framework Agreement between NHS Supply Chain and successful suppliers will reserve the right to purchase the same or similar supplies from suppliers not appointed to the Framework at its sole discretion. Estimated total value over the 4 year agreement is approximately £960,000,000 to £1,067,000,000 Excluding VAT. Please note it is expected that the yearly spend for years 2 , 3 and 4 of the Framework Agreement will rise significantly. Following the National Institute for Health and Care Excellence (NICE) Technology Appraisal TA943 Overview | Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes | Guidance | NICE published 19th December 2023 and the NHS England Implementation Plan https://www.england.nhs.uk/long-read/hybrid-closed-loop-technologies-5-year-implementation-strategy/ NHS Supply Chain intends to enter into arrangements under which it will be entitled to purchase supplies which it will make available for purchase by 1) any NHS Trust; 2) any other NHS entity; 3) any government department, agency or other statutory body and/or 4) any private sector entity active in the UK healthcare sector. Only NHS Supply Chain can order from the Framework Agreement and enter into contracts under it. Lot Lot 1: Insulin Pumps This Lot aims to offer Patch Insulin Pumps and Tethered Insulin Pumps and associated consumables or accessories. It is expected that the yearly spend for years 2 , 3 and 4 of the Framework Agreement will rise significantly. Following the National Institute for Health and Care Excellence (NICE) Technology Appraisal TA943 Overview | Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes | Guidance | NICE published 19th December 2023 and the NHS England Implementation Plan https://www.england.nhs.uk/long-read/hybrid-closed-loop-technologies-5-year-implementation-strategy/ Additional information: Precise quantities are unknown. It is anticipated that initial expenditure will be in the region of £140,000,000 - £150,000,000 in the first year. These are approximate only and the values may vary depending on the requirements of those bodies purchasing under the Framework Agreement. It is expected that the yearly spend for years 2 , 3 and 4 of the Framework Agreement will rise significantly. Lot Lot 2: Continuous Glucose Monitors This Lot aims to offer Continuous Glucose Monitors and associated consumables or accessories. It is expected that the yearly spend for years 2 , 3 and 4 of the Framework Agreement will rise significantly. Following the National Institute for Health and Care Excellence (NICE) Technology Appraisal TA943 Overview | Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes | Guidance | NICE published 19th December 2023 and the NHS England Implementation Plan https://www.england.nhs.uk/long-read/hybrid-closed-loop-technologies-5-year-implementation-strategy/ Additional information: Precise quantities are unknown. It is anticipated that initial expenditure will be in the region of £75,000,000 to £95,000,000 in the first year. These are approximate only and the values may vary depending on the requirements of those bodies purchasing under the Framework Agreement. It is expected that the yearly spend for years 2 , 3 and 4 of the Framework Agreement will rise significantly. Lot Lot 3: Software and Diabetes Management Systems Applications and/or software that contributes to the functionality of a closed loop insulin delivery system. Products that connect with blood glucose sensors and insulin pumps to automatically increase, decrease, or stop the delivery of insulin in response to the glucose levels of people with diabetes. Diabetes Management Systems that allow for the uploading of information from insulin pumps, CGM’s, glucose meters, and mobile applications. It is expected that the yearly spend for years 2 , 3 and 4 of the Framework Agreement will rise significantly. Following the National Institute for Health and Care Excellence (NICE) Technology Appraisal TA943 Overview | Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes | Guidance | NICE published 19th December 2023 and the NHS England Implementation Plan https://www.england.nhs.uk/long-read/hybrid-closed-loop-technologies-5-year-implementation-strategy/ Additional information: Precise quantities are unknown. It is anticipated that initial expenditure will be in the region of £15,000 to £17,000 in the first year. These are approximate only and the values may vary depending on the requirements of those bodies purchasing under the Framework Agreement. It is expected that the yearly spend for years 2 , 3 and 4 of the Framework Agreement will rise significantly.